Kiniksa Pharmaceuticals, Ltd. | Mid-cap | Healthcare

TL;DR: Financial Overview - Revenue, Profits & Key Metrics

Latest Quarterly: Mar 2025

Income Metrics

Revenue 137.8M
Gross Profit 76.1M 55.25%
Operating Income 13.3M 9.63%
Net Income 8.5M 6.20%
EPS (Diluted) $0.11

Balance Sheet Metrics

Total Assets 599.3M
Total Liabilities 141.8M
Shareholders Equity 457.5M
Debt to Equity 0.31

Cash Flow Metrics

Operating Cash Flow 31.0M
Free Cash Flow 22.2M

Revenue & Profitability Trend

Kiniksa Income Statement From 2020 to 2024

Metric20242023202220212020
Revenue i423.2M270.3M220.2M38.5M0
Cost of Goods Sold i60.9M33.4M22.9M9.1M0
Gross Profit i362.3M236.9M197.3M29.4M0
Gross Margin % i85.6%87.6%89.6%76.4%0.0%
Operating Expenses
Research & Development i111.6M76.1M65.5M99.3M112.0M
Selling, General & Administrative i168.0M129.4M98.0M85.9M45.3M
Other Operating Expenses i128.3M56.5M24.1M835.0K-
Total Operating Expenses i407.9M262.0M187.5M186.1M157.4M
Operating Income i-45.6M-25.2M9.8M-156.6M-157.4M
Operating Margin % i-10.8%-9.3%4.4%-406.4%0.0%
Non-Operating Items
Interest Income i--1.3M97.0K1.1M
Interest Expense i-----
Other Non-Operating Income9.5M8.5M1.3M97.0K-
Pre-tax Income i-36.2M-16.7M11.0M-156.5M-156.2M
Income Tax i7.0M-30.7M-172.3M1.4M5.2M
Effective Tax Rate % i0.0%0.0%-1,563.0%0.0%0.0%
Net Income i-43.2M14.1M183.4M-157.9M-161.4M
Net Margin % i-10.2%5.2%83.3%-409.7%0.0%
Key Metrics
EBITDA i-43.9M-22.9M12.2M-154.3M-155.0M
EPS (Basic) i$-0.60$0.20$2.64$-2.30$-2.61
EPS (Diluted) i$-0.60$0.20$2.60$-2.30$-2.61
Basic Shares Outstanding i7142415970058952693822756857681061842722
Diluted Shares Outstanding i7142415970058952693822756857681061842722

Income Statement Trend

Kiniksa Balance Sheet From 2020 to 2024

Metric20242023202220212020
Assets
Current Assets
Cash & Equivalents i183.6M108.0M122.7M122.5M114.0M
Short-term Investments i60.0M98.4M67.9M59.7M209.4M
Accounts Receivable i41.7M21.3M12.7M4.0M0
Inventory i26.4M31.1M21.6M3.7M0
Other Current Assets20.1M17.5M10.5M6.6M9.6M
Total Current Assets i331.8M276.3M243.1M196.4M333.2M
Non-Current Assets
Property, Plant & Equipment i14.6M15.9M9.4M9.8M11.2M
Goodwill i16.2M17.2M18.2M19.2M0
Intangible Assets i16.2M17.2M18.2M19.2M-
Long-term Investments-----
Other Non-Current Assets221.5M220.1M191.3M8.7M5.6M
Total Non-Current Assets i248.8M250.0M216.6M36.4M16.2M
Total Assets i580.6M526.3M459.7M232.8M349.5M
Liabilities
Current Liabilities
Accounts Payable i2.0M8.2M7.9M1.9M503.0K
Short-term Debt i2.0M2.3M3.3M3.4M2.1M
Current Portion of Long-term Debt-----
Other Current Liabilities16.1M8.2M5.8M1.5M37.0K
Total Current Liabilities i100.6M63.7M47.1M44.8M31.8M
Non-Current Liabilities
Long-term Debt i7.9M10.0M2.6M2.7M4.9M
Deferred Tax Liabilities i-----
Other Non-Current Liabilities1.8M1.9M1.8M270.0K805.0K
Total Non-Current Liabilities i41.5M23.8M16.5M2.9M5.7M
Total Liabilities i142.1M87.5M63.5M47.8M37.5M
Equity
Common Stock i20.0K20.0K19.0K18.0K18.0K
Retained Earnings i-521.1M-478.0M-492.0M-675.4M-517.5M
Treasury Stock i-----
Other Equity-----
Total Shareholders Equity i438.4M438.8M396.1M185.0M311.9M
Key Metrics
Total Debt i9.9M12.3M5.9M6.0M7.0M
Working Capital i231.2M212.6M196.0M151.6M301.4M

Balance Sheet Composition

Kiniksa Cash Flow Statement From 2020 to 2024

Metric20242023202220212020
Operating Activities
Net Income i-43.2M14.1M183.4M-157.9M-161.4M
Depreciation & Amortization i1.7M2.3M2.4M2.4M2.4M
Stock-Based Compensation i30.7M27.1M25.1M25.2M20.9M
Working Capital Changes i-16.2M-8.5M-15.0M-12.6M-16.9M
Operating Cash Flow i-15.7M4.3M13.4M-140.3M-149.2M
Investing Activities
Capital Expenditures i-252.0K-130.0K-14.0K-415.0K-283.0K
Acquisitions i-----
Investment Purchases i-202.0M-204.9M-135.9M-157.2M-430.2M
Investment Sales i239.9M175.5M127.8M306.3M407.0M
Investing Cash Flow i37.7M-29.6M-8.1M148.6M-23.4M
Financing Activities
Share Repurchases i-5.0M-2.2M-901.0K00
Dividends Paid i-----
Debt Issuance i-----
Debt Repayment i-----
Financing Cash Flow i-5.0M-2.2M2.5M0227.1M
Free Cash Flow i25.4M13.2M5.7M-146.7M-136.8M
Net Change in Cash i16.9M-27.4M7.9M8.3M54.4M

Cash Flow Trend

Kiniksa Key Financial Ratios

Valuation Ratios

P/E Ratio (TTM) 769.80
Forward P/E 69.98
Price to Book 5.76
Price to Sales 5.39
PEG Ratio -1.54

Profitability Ratios

Profit Margin 0.90%
Operating Margin 12.86%
Return on Equity 1.03%
Return on Assets 0.47%

Financial Health

Current Ratio 3.57
Debt to Equity 1.97
Beta 0.16

Per Share Data

EPS (TTM) $0.05
Book Value per Share $6.69
Revenue per Share $7.30

Peer Financial Comparison

CompanyMarket CapP/E RatioP/B RatioROEProfit MarginDebt/Equity
knsa2.9B769.805.761.03%0.90%1.97
Zoetis 65.1B25.1613.0652.77%27.83%137.01
Haleon Plc - ADR 41.4B19.895.079.38%13.81%53.41
Regencell Bioscience 8.5B-1,992.171,227.86-47.77%0.00%0.00
Alkermes plc 5.3B15.003.1623.94%23.15%4.47
Prestige Consumer 3.8B17.922.0712.30%18.86%56.91

Financial data is updated regularly. All figures are in the company's reporting currency.